

ASX RELEASE

23 July 2019

Amplia Therapeutics Reports Lead Candidate Preclinical Data

Amplia Therapeutics recently received positive preclinical efficacy data from the laboratory of Dr Alan Serrels at the University of Edinburgh. Dr Serrels is a world-leading researcher in FAK biology and an advisor to Amplia: his group established one of the key preclinical models demonstrating the effects of FAK inhibitors in a squamous cell carcinoma (SCC) cancer disease model.

Amplia's CEO, Dr John Lambert commented that "we consider the results of this study to be highly encouraging and the data further confirms Amplia's view that our lead drug candidate AMP945 should be advanced into clinical development as quickly as possible."

Although Amplia intends to initially advance AMP945 as a combination cancer therapy, the experiments recently completed were designed to provide an understanding of the effects of AMP945 alone. Future studies will assess the effects of AMP945 when used in combination with other immune oncology products.

The data reveals that, when used as a single agent in Dr Serrels' SCC cancer disease model, AMP945 exerts several effects that are consistent with the potential to restore the patient's own antitumour immune response.




Figure: Effects of AMP945 in the mouse SCC cancer disease model

The effects of AMP945 in the mouse SCC cancer disease model include the following:

- After 15 days' treatment, tumour volumes in mice treated with AMP945 were approximately half that of mice treated with the non-active control vehicle alone.
- Levels of pY397 FAK, the phosphorylated form of FAK in tumour tissues, were undetectable indicating complete inhibition of FAK *in vivo*.
- A statistically significant reduction in tumour-associated CD206⁺ macrophages and granulocytic myeloid-derived suppressor cells. CD206⁺ macrophages and gMDSCs are both known to contribute to

suppression of antitumour immune responses, as well as contributing to tumour growth and metastases. (Panels A and B)

- A statistically significant reduction of tumour-associated endothelial cells, indicative of reduced angiogenesis (formation of new blood vessels) in the tumour tissue. (Panel C)

Further preclinical studies are planned and the company will report on these in due course.

- End -

For Further Information

John Lambert, CEO

+61 409 525 259

www.ampliatx.com

About Amplia Therapeutics Limited

Amplia Therapeutics Limited is an Australian pharmaceutical company advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. FAK is an increasingly important target in the field of cancer immunology and Amplia has a particular development focus in pancreatic and ovarian cancer. FAK also plays a significant role in a number of chronic diseases, such as idiopathic pulmonary fibrosis (IPF).